Although Dendreon's (NASDAQ:DNDN) performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market.

Austin Smith and David Williamson have no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.